BofA analyst Koichi Mamegano upgraded Takeda Pharmaceutical to Buy from Neutral with a $20 price target. The company has made progress in paying down interest-bearing debt and has been active in acquiring candidates like TYK2 inhibitor TASK-279, the analyst tells investors in a research note. After having been a "value stock" for a long time, expansion of the company’s pipeline to support future growth will likely have positive share price implications, contends the firm.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TAK: